Skip to main
LSTA
LSTA logo

LSTA Stock Forecast & Price Target

LSTA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lisata Therapeutics Inc has shown significant progress in the development of its lead investigational drug, certepetide, which aims to enhance the efficacy of anti-cancer therapies for solid tumors. Preliminary data from Cohort A and further insights from Cohort B indicate a promising trend in overall survival, with a notable number of complete responses, suggesting its potential to improve progression-free survival (PFS) and overall response rate (ORR) for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). The advancements in clinical data reinforce the potential value of certepetide in treating complex conditions, contributing to a positive financial outlook for the company.

Bears say

Lisata Therapeutics Inc's stock outlook is negatively influenced by several fundamental factors, primarily including the potential for failed or inconclusive clinical trials, which could significantly hinder the development of its investigational product, certepetide. Additionally, the company's ability to secure adequate funding remains critical, as insufficient financial resources could stall or prevent the progress of its drug development efforts. The combination of these risks poses considerable uncertainty regarding the future valuation and prospects for reaching key financial targets.

LSTA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lisata Therapeutics Inc (LSTA) Forecast

Analysts have given LSTA a Strong Buy based on their latest research and market trends.

According to 2 analysts, LSTA has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lisata Therapeutics Inc (LSTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.